NCT00055809View on ClinicalTrials.gov

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

June 30, 2007

Conditions
Metastatic Gastrointestinal Carcinoid TumorRecurrent Gastrointestinal Carcinoid TumorRegional Gastrointestinal Carcinoid Tumor
Interventions
BIOLOGICAL

PEG-interferon alfa-2b

Given SC

BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Optional correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00055809 - Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors | Biotech Hunter | Biotech Hunter